Non-invasive. Precise. Life-changing
LiquidDx™ circulating tumour DNA (ctDNA) liquid biopsy is a cancer test that checks for cancer cells in your blood instead of taking a tissue sample from your body. This test uses modern technology called next-generation sequencing to look for tiny pieces of DNA from cancer cells in your bloodstream. This type of testing is more accurate and specific than traditional cancer tests and can provide important information about the changes in your cancer cells.
Circulating Tumour DNA as an Alternative to Tissue Biopsies
LiquidDX™ leverages circulating tumour DNA (ctDNA) found in a patient’s bloodstream to deliver actionable genomic insights without the need for invasive tissue biopsies. By analyzing a patient's blood sample, ctDNA can provide information about the genetic mutations present in the tumour, which can help inform treatment decisions and monitor the effectiveness of therapy. LiduidDx can assess numerous tissues and biomarkers from plasma samples. Comprehensive genomic profiling using ctDNA consolidates hundreds of markers into a single assay.
Early and Actionable Insights for Better Treatment Decisions
Unlike tissue biopsies, which require specialized surgical or technical expertise, liquid biopsy samples can be collected through standard phlebotomy procedures, making the process more accessible, cost-effective, and with faster turnaround times. The reduced risk of procedure-related complications further strengthens its clinical utility. Reflecting this value, multiple international guidelines now recommend liquid biopsy for specific tumor types, particularly when tissue samples are unavailable, such as in non-small cell lung cancer.
Adding CGP from liquid biopsy further enables precision medicine
ctDNA analysis provides powerful insights into tumor biology. It helps overcome tissue sampling bias by capturing tumor heterogeneity and can be leveraged to monitor disease progression, treatment response, and acquired resistance. With sequencing methods capable of detecting emerging mutations, liquid biopsy is uniquely positioned to track clonal evolution and reveal new alterations, including those arising in tissues beyond the original tumor site.
ctDNA analysis has been refined to become a tool for assessing tumour heterogeneity and overcoming tissue sampling bias.
+15%
more clinically relevant mutations
Liquid biopsy is complementary to tissue
~20%
of the time clinical NGS is prevented from FFPE samples in advanced cancers
Liquid biopsy for insufficient tissue quality or quantity
↓ 3x
decrease in screening time
Clinical trials benefit from liquid biopsy
↑ 2.3x
increase in enrollment rate in advanced gastrointestinal cancer compared to CGP from tissue only
Clinical trials benefit from liquid biopsy
Liquid biopsy is recommended today by guidelines
Different tumor types may have specific use cases for liquid biopsy, such as when:
-
Patient is medically unfit for a tissue biopsy
-
Insufficient material is available
-
Tissue biopsy is unavailable
Transform Cancer Care with Precision Medicine
Our comprehensive genomic profiling tests provide information about clinically relevant biomarkers and genomic alterations to help match patients to approved targeted therapies, immunotherapies, and clinical trial options — giving physicians and patients powerful actionable insights for navigating cancer care.